ICC    Home E-mail Print Search
 
ICC Home
About the awards
Awards objectives
Eligibility criteria
Int. judging panel
2006 recipients
Nomination procedure
Topics
Previous awards
News stories
Links
Millennium development goals
IBLF
UNDP
ICC Home
Contact & media
Downloads
Brochure
Nomination form
 Alliance for the Elimination of Lymphatic Filariasis (GAELF)
Lead partner: GlaxoSmithKline

LF_b.gif
Sri Lankan nurse delivers medicine to villagers to break the cycle of lymphatic filariasis infection.

GSK is an active partner in the Global Alliance to Eliminate Lymphatic Filariasis (commonly known as elephantiasis). This disfiguring tropical disease, passed to humans by mosquitos, threatens more than one billion people in 83 countries in tropical and subtropical areas of Asia, Africa, the Pacific Islands and the Caribbean. It is one of the world's leading causes of disability and costs affected areas billions of dollars each year in lost productivity. GSK has committed itself to donating its anti-parasitic medicine, albendazole, to all endemic countries for as long as necessary to eliminate this disease. Albendazole, if given with another anti-parasitic medicine every year for at least five years, can break the cycle of lymphatic filariasis infection. The company has donated over 440 million treatments to 40 countries so over 100 million people, including 30 million children, have already benefited from the program.


Website: www.filariasis.org or www.gsk.com/filariasis

Most popular ICC articles ICC Archives
Court of Arbitration Bookstore Policy Events Institute WCF ATA CCS
 
  Copyright 2008 International Chamber of Commerce
Copyright, trademark and privacy notice

ICC Copyright

RSS

Add to My Yahoo!  Add to Google